Akebia Therapeutics, Inc.
Compositions and methods for treating anemia
Last updated:
Abstract:
Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.
Status:
Grant
Type:
Utility
Filling date:
31 Mar 2016
Issue date:
10 May 2022